| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | T-complex protein 1 subunit zeta; TCP-1-zeta; CCT-zeta; CCT-zeta-1; Tcp20 |
| Entrez GeneID | 908; |
| WB Predicted band size | 60kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from internal of human CCT6A. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于 **CDC2(Phospho-Tyr15)抗体** 的模拟参考文献示例(仅供参考，实际文献需通过数据库验证)：
---
1. **文献名称**：*"Phosphorylation of CDC2 on Tyr15 regulates mitotic entry in response to DNA damage"*
**作者**：Smith A, Jones B, et al.
**摘要**：本研究揭示了DNA损伤后，CDC2在Tyr15位点的磷酸化通过抑制激酶活性延迟细胞进入有丝分裂。作者使用特异性抗Tyr15磷酸化抗体，通过免疫印迹和免疫荧光验证了ATR/Chk1通路对此修饰的调控作用。
2. **文献名称**：*"Characterization of a monoclonal antibody specific for CDC2 phosphorylated at Tyr15"*
**作者**：Lee C, Brown D, et al.
**摘要**：该文献报道了一种高特异性抗CDC2(p-Tyr15)单克隆抗体的开发与验证。实验证明该抗体可用于免疫沉淀和免疫组化，且在HeLa细胞中成功检测到DNA复制检查点激活后的CDC2磷酸化状态。
3. **文献名称**：*"Temporal regulation of CDC2 Tyr15 phosphorylation during oocyte maturation in Xenopus"*
**作者**：Garcia-Ruiz S, Zhang H, et al.
**摘要**：通过使用抗CDC2(p-Tyr15)抗体，研究者发现非洲爪蟾卵母细胞成熟过程中，Tyr15磷酸化水平周期性波动，并与细胞周期蛋白B1的降解协同调控CDC2活性。
4. **文献名称**：*"CDC2 Tyr15 phosphorylation as a biomarker for tumor response to chemotherapy"*
**作者**：Wang Y, Chen L, et al.
**摘要**：该研究利用抗CDC2(p-Tyr15)抗体分析肿瘤样本，发现化疗药物通过诱导Tyr15磷酸化阻滞细胞周期，且磷酸化水平与患者预后显著相关。
---
**注意**：以上文献为模拟示例，实际引用时请通过PubMed、Google Scholar等数据库检索真实文献并核对信息。
CDC2 (Phospho-Tyr15) antibodies are essential tools for studying the regulation of cell cycle progression, particularly during the G2/M transition. CDC2 (Cell Division Cycle 2), also known as CDK1 (Cyclin-Dependent Kinase 1), is a critical serine/threonine kinase that partners with cyclin B to form the Maturation-Promoting Factor (MPF), which drives mitotic entry. Its activity is tightly controlled by phosphorylation and dephosphorylation events. Phosphorylation at Tyr15. mediated by the Wee1 kinase, inhibits CDC2 activity by preventing ATP binding, thereby delaying mitotic initiation until DNA repair or other checkpoints are resolved. Dephosphorylation of Tyr15 by CDC25 phosphatases activates CDC2. enabling cell cycle progression.
Antibodies specific to CDC2 phosphorylated at Tyr15 are widely used to monitor the inhibitory phosphorylation status of CDC2 in response to DNA damage, replication stress, or checkpoint activation. These antibodies facilitate the detection of cell cycle arrest in G2 phase, making them valuable in cancer research, drug development, and studies of cell cycle regulation. Applications include Western blotting, immunofluorescence, and flow cytometry to assess checkpoint signaling pathways, evaluate chemotherapeutic agent efficacy, or explore mechanisms underlying genomic stability. Dysregulation of CDC2 phosphorylation is linked to tumorigenesis, making these antibodies relevant for biomarker discovery and therapeutic targeting in oncology.
×
